Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate

被引：67

作者：

Murthy, Madhukiran H. ^{[1
]}

Olson, Michael E. ^{[2
]}

Wickert, Robert W. ^{[2
]}

Fey, Paul D. ^{[2
]}

Jalali, Ziba ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med & Infect Dis, Omaha, NE 68198 USA

[2] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA

来源：

JOURNAL OF MEDICAL MICROBIOLOGY | 2008年 / 57卷 / 08期

关键词：

D O I：

10.1099/jmm.0.2008/000588-0

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in mprF, resulting in a T345A substitution, associated with non-susceptibility to daptomycin.

引用

页码：1036 / 1038

页数：3

共 17 条

[1] DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS [J].

ALBORN, WE ;

ALLEN, NE ;

PRESTON, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2282-2287

[2]

[Anonymous], 2007, Document M100-S17

[3] PULSED-FIELD GEL-ELECTROPHORESIS AS A REPLACEMENT FOR BACTERIOPHAGE-TYPING OF STAPHYLOCOCCUS-AUREUS [J].

BANNERMAN, TL ;

HANCOCK, GA ;

TENOVER, FC ;

MILLER, JM .

JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (03) :551-555

[4] Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus [J].

Cui, LZ ;

Tominaga, E ;

Neoh, HM ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :1079-1082

[5] Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus [J].

Diep, BA ;

Gill, SR ;

Chang, RF ;

Phan, TH ;

Chen, JH ;

Davidson, MG ;

Lin, F ;

Lin, J ;

Carleton, HA ;

Mongodin, EF ;

Sensabaugh, GF ;

Perdreau-Remington, F .

LANCET, 2006, 367 (9512) :731-739

[6] Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections [J].

Eisenstein, BI .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1159-1169

[7] Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus [J].

Fey, PD ;

Saïd-Salim, B ;

Rupp, ME ;

Hinrichs, SH ;

Boxrud, DJ ;

Davis, CC ;

Kreiswirth, BN ;

Schlievert, PM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :196-203

[8] Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus [J].

Friedman, L ;

Alder, JD ;

Silverman, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2137-2145

[9] Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding [J].

Jones, Tiffanny ;

Yeaman, Michael R. ;

Sakoulas, George ;

Yang, Soo-Jin ;

Proctor, Richard A. ;

Sahl, Hans-Georg ;

Schrenzel, Jacques ;

Xiong, Yan Q. ;

Bayer, Arnold S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :269-278

[10] Mechanisms of daptomycin resistance in Staphylococcus aureus [J].

Kaatz, Glenn W. ;

Lundstrom, Tammy S. ;

Seo, Susan M. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (04) :280-287

← 1 2 →